JP6944375B2 - 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置 - Google Patents

発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置 Download PDF

Info

Publication number
JP6944375B2
JP6944375B2 JP2017551276A JP2017551276A JP6944375B2 JP 6944375 B2 JP6944375 B2 JP 6944375B2 JP 2017551276 A JP2017551276 A JP 2017551276A JP 2017551276 A JP2017551276 A JP 2017551276A JP 6944375 B2 JP6944375 B2 JP 6944375B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
patient
binding fragment
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017551276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511609A (ja
JP2018511609A5 (enExample
Inventor
カミール ベドロシアン，
カミール ベドロシアン，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド, アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2018511609A publication Critical patent/JP2018511609A/ja
Publication of JP2018511609A5 publication Critical patent/JP2018511609A5/ja
Application granted granted Critical
Publication of JP6944375B2 publication Critical patent/JP6944375B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2017551276A 2015-03-31 2016-03-29 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置 Active JP6944375B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562140711P 2015-03-31 2015-03-31
US62/140,711 2015-03-31
PCT/US2016/024624 WO2016160756A2 (en) 2015-03-31 2016-03-29 Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents

Publications (3)

Publication Number Publication Date
JP2018511609A JP2018511609A (ja) 2018-04-26
JP2018511609A5 JP2018511609A5 (enExample) 2019-05-09
JP6944375B2 true JP6944375B2 (ja) 2021-10-06

Family

ID=55702135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017551276A Active JP6944375B2 (ja) 2015-03-31 2016-03-29 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置

Country Status (4)

Country Link
US (1) US20190135903A1 (enExample)
EP (1) EP3277715A2 (enExample)
JP (1) JP6944375B2 (enExample)
WO (1) WO2016160756A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
EP3592386A4 (en) 2017-03-06 2021-01-13 The Trustees Of The University Of Pennsylvania ANTI-C5 ANTIBODIES AND USES THEREOF
ES2965486T3 (es) * 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
MX2020003619A (es) * 2017-10-04 2020-10-28 Alexion Pharma Inc Dosificacion y administracion de los anticuerpos anti-c5 para el tratamiento de los pacientes con glomerulonefritis membranoproliferativa.
JP7518764B2 (ja) 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
EP3802603A1 (en) * 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体の産生方法
CN113038967B (zh) 2018-09-06 2026-07-14 宾夕法尼亚大学理事会 人源化抗c5抗体及其用途
US12240893B2 (en) * 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
HUE066795T2 (hu) * 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
PT2970974T (pt) * 2013-03-14 2017-11-29 Alnylam Pharmaceuticals Inc Composições de irna de componente do complemento c5 e métodos para a sua utilização
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics

Also Published As

Publication number Publication date
WO2016160756A2 (en) 2016-10-06
JP2018511609A (ja) 2018-04-26
WO2016160756A3 (en) 2016-11-24
EP3277715A2 (en) 2018-02-07
US20190135903A1 (en) 2019-05-09
WO2016160756A8 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
JP2018511609A (ja) 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置
JP6672383B2 (ja) 間葉及び上皮間葉形質転換循環腫瘍細胞のための特異的検出ツール
JP6936784B2 (ja) グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法
RU2727911C2 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
RU2743152C2 (ru) Гуманизированные анти-тау-антитела
JP6449441B2 (ja) ＦｃＲｎ特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物
AU2012247762B2 (en) Dosage regimen for administering a CD19xCD3 bispecific antibody to patients at risk for potential adverse effects
TWI551609B (zh) 抗－顆粒溶解素抗體及其應用
WO2021259199A1 (zh) 抗cd73抗体及其用途
WO2014016737A1 (en) Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
JP7527589B2 (ja) 切断型の変異型Ｃａｌｒｅｔｉｃｕｌｉｎに結合する抗体、及び骨髄増殖性腫瘍の診断、予防又は治療薬
JP2020100631A (ja) 多発性硬化症の併用治療
CN112442123B (zh) 抗cd47的单克隆抗体及其用途
JP2020511963A (ja) ヒトアルファ−シヌクレインに対する抗体
JP2021525718A (ja) 小児患者における発作性夜間ヘモグロビン尿症（ｐｎｈ）の治療のための抗ｃ５抗体の用量および投与
AU2021251486A1 (en) Anti-PHF-TAU antibodies and uses thereof
WO2022087339A1 (en) Methods of treating patients having complement disorders using anti-c5 antibodies
JP7773154B2 (ja) コロナウイルススパイク蛋白に対するヒト抗体またはその抗原結合断片
CN115996752B (zh) 用于治疗癫痫的组合物和方法
JP7818219B2 (ja) Ｅｌｔｄ１に対するモノクローナル抗体及びその使用
JP2016510870A (ja) 補体因子ｈ関連タンパク質１検出のための剤、キットおよび方法
WO2018084236A1 (ja) プロレニン受容体に対する抗体またはその抗原結合断片、およびその用途
WO2023232826A1 (en) Biomarkers of il7r modulator activity
CA3199648A1 (en) Il-7 binding proteins and their use in medical therapy
WO2021175191A1 (zh) 抗tim-3抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210910

R150 Certificate of patent or registration of utility model

Ref document number: 6944375

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250